JPRN-jRCT2080223650未知1 期
Placebo-controlled, double-blind, repeated oral dose, clinical pharmacology study of TMG-123 in patients with type 2 diabetes mellitus
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- Male
入选标准
- •Patients with type 2 diabetes mellitus
排除标准
- •Subjects with type 1 diabetes mellitus or diabetes due to other specific mechanisms or diseases
- •Subjects judged as not eligible by the investigator or sub-investigators for other reasons
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneaous injections of a sustained-release implant of ZT-1 in patients with moderate Alzheimer’s Disease (AD)EUCTR2006-005161-18-GBDebiopharm128
已完成
不适用
A placebo controlled, single-blind, single oral dose study to determine the safety and immunogenicity of M01ZH09 typhoid vaccine (oral live S. typhi [Ty2 aroC- ssaV-] ZH9) in healthy paediatric subjects, aged five to 14 years inclusive, of Vietnamese origiTyphoid feverTyphoid fever prophylaxisInfections and InfestationsISRCTN91111837Emergent Product Development UK Ltd (UK)150
进行中（未招募）
1 期
Dose response study of EMA401 in patients with post-herpetic neuralgia (PHN)Post-herpetic neuralgiaMedDRA version: 20.0Level: PTClassification code 10036376Term: Post herpetic neuralgiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-000280-16-SKovartis Pharma AG360
进行中（未招募）
1 期
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intentEUCTR2020-003720-16-DEovartis Pharma AG195
进行中（未招募）
1 期
Dose response study of EMA401 in patients with post-herpetic neuralgia (PHN)Post-herpetic neuralgiaMedDRA version: 20.0 Level: PT Classification code 10036376 Term: Post herpetic neuralgia System Organ Class: 10029205 - Nervous system disordersEUCTR2016-000280-16-HUovartis Pharma AG360